

Table 1.5  
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)  
By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence <sup>a</sup> (2014-2018)			US Mortality <sup>b</sup> (2014-2018)			Survival <sup>c</sup> (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	460.9	495.8	439.5	156.3	185.9	134.3	68.0	66.4	69.5
Oral Cavity & Pharynx:	12.1	18.2	6.7	2.5	3.9	1.4	68.2	68.0	68.7
Lip	0.7	1.1	0.4	0.0	0.0	0.0	90.8	91.4	89.3
Tongue	4.0	6.0	2.1	0.7	1.0	0.4	69.4	69.8	68.1
Salivary gland	1.3	1.7	1.0	0.3	0.4	0.2	70.0	63.8	79.6
Floor of mouth	0.5	0.7	0.3	0.0	0.0	0.0	52.6	50.4	57.9
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	61.0	58.8	63.9
Nasopharynx	0.4	0.5	0.2	0.1	0.2	0.1	57.4	55.6	62.3
Tonsil	2.3	4.0	0.8	0.3	0.5	0.1	76.9	77.3	74.8
Oropharynx	0.6	0.9	0.2	0.3	0.5	0.1	52.7	55.3	42.5
Hypopharynx	0.5	0.9	0.2	0.1	0.2	0.0	39.7	39.4	41.2
Other oral cavity & pharynx	0.3	0.4	0.1	0.4	0.6	0.2	54.0	56.9	42.7
Digestive System:	79.0	95.5	64.8	39.8	50.8	30.4	43.9	41.6	46.8
Esophagus	4.6	7.8	1.8	4.1	7.4	1.4	20.6	20.1	22.7
Stomach	6.5	8.7	4.6	2.6	3.5	1.9	31.1	27.9	36.6
Small intestine	2.4	2.7	2.1	0.4	0.5	0.3	69.4	69.2	69.7
Colon & Rectum:	37.4	42.5	33.0	13.4	15.9	11.3	65.1	64.7	65.5
Colon	26.3	28.7	24.2	-	-	-	64.2	64.0	64.4
Rectum	11.2	13.8	8.8	-	-	-	67.1	66.1	68.4
Anus, anal canal & anorectum	2.1	1.6	2.5	0.3	0.2	0.3	69.7	65.0	72.1
Liver & intrahepatic bile duct	8.2	12.5	4.5	6.2	9.0	3.8	19.3	19.3	19.2
Gallbladder	1.1	0.8	1.4	0.5	0.4	0.7	19.6	21.2	18.8
Other biliary	1.8	2.2	1.4	0.5	0.5	0.4	18.8	20.2	17.2
Pancreas	13.3	15.2	11.7	11.0	12.8	9.5	10.7	10.9	10.6
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	54.9	52.3	57.3
Peritoneum, omentum & mesentery	0.5	0.1	0.9	0.3	0.1	0.4	32.6	38.0	32.3
Other digestive system	0.8	0.9	0.7	0.4	0.4	0.3	7.7	6.8	8.7
Respiratory System:	58.7	66.6	52.6	40.5	49.1	33.8	24.5	22.7	26.6
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.1	0.2	0.1	59.5	59.4	59.8
Larynx	2.8	4.9	1.1	0.9	1.6	0.4	61.8	62.4	59.0
Lung & bronchus	54.9	60.5	50.8	39.3	47.1	33.3	21.7	18.1	25.4
Pleura <sup>d</sup>	0.0	0.0	0.0	0.1	0.2	0.0	22.1	21.0	21.7
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	55.7	53.9	60.5
Bones & joints	1.1	1.2	0.9	0.5	0.6	0.4	66.3	63.4	69.9
Soft tissue (including heart)	3.5	4.3	2.9	1.3	1.6	1.1	65.1	65.2	65.1
Skin (excl. basal & squamous):	29.6	37.8	23.5	3.8	5.8	2.2	92.0	90.1	94.4
Melanoma of the skin	27.4	34.7	22.1	2.6	3.9	1.7	92.8	91.0	95.0
Other non-epithelial skin	2.2	3.1	1.5	1.1	1.9	0.5	80.8	78.0	85.1
Breast	69.7	1.2	131.8	10.8	0.3	19.6	91.2	84.8	91.3
Breast ( <i>in situ</i> )	16.6	0.1	32.1	-	-	-	100.0	99.9	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>c</sup> SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5 - continued  
 Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)  
 By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence <sup>a</sup> (2014-2018)			US Mortality <sup>b</sup> (2014-2018)			Survival <sup>c</sup> (%) (2011-2017)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.6	-	52.7	8.0	-	14.8	71.5	-	71.5
Cervix uteri	3.7	-	7.3	1.1	-	2.1	67.6	-	67.6
Corpus uteri	14.5	-	27.8	1.3	-	2.3	84.8	-	84.8
Uterus, NOS	0.4	-	0.8	1.2	-	2.2	28.5	-	28.5
Ovary <sup>d</sup>	6.0	-	11.3	3.8	-	6.9	49.0	-	49.0
Vagina	0.4	-	0.7	0.1	-	0.2	48.7	-	48.7
Vulva	1.5	-	2.8	0.3	-	0.6	70.6	-	70.6
Other female genital system	1.0	-	1.9	0.2	-	0.4	49.3	-	49.3
Male Genital System:	52.3	112.3	-	7.6	18.4	-	97.1	97.1	-
Prostate	48.2	104.1	-	7.4	17.9	-	97.4	97.4	-
Testis	3.6	7.1	-	0.1	0.3	-	94.9	94.9	-
Penis	0.4	0.9	-	0.1	0.2	-	65.2	65.2	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	84.7	84.7	-
Urinary System:	39.7	62.2	21.5	8.5	13.7	4.7	76.1	76.6	74.8
Urinary bladder	21.7	37.5	9.3	4.5	7.8	2.2	77.5	78.7	73.6
Kidney & renal pelvis	17.0	23.2	11.6	3.8	5.5	2.3	75.6	74.8	76.9
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	48.6	48.9	48.3
Other urinary system	0.4	0.7	0.2	0.1	0.2	0.1	48.6	50.9	43.5
Eye & Orbit	1.0	1.1	0.9	0.1	0.1	0.1	83.5	83.4	83.7
Brain & Nervous System: <sup>e</sup>	7.1	8.3	6.0	4.8	5.9	3.9	31.2	29.9	32.9
Brain	6.6	7.9	5.5	-	-	-	28.2	27.2	29.5
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	79.8	78.5	81.2
Endocrine System:	17.0	9.4	24.6	0.8	0.9	0.7	97.1	93.7	98.3
Thyroid	16.2	8.5	23.9	0.5	0.5	0.5	98.5	96.4	99.1
Other endocrine & thymus	0.8	0.9	0.7	0.3	0.3	0.3	65.2	66.8	63.3
Lymphoma:	23.3	28.0	19.5	5.9	7.7	4.5	75.5	74.3	76.9
Hodgkin lymphoma	2.8	3.1	2.5	0.3	0.4	0.2	88.5	88.0	89.2
Non-Hodgkin lymphoma	20.6	24.9	17.0	5.6	7.3	4.3	73.6	72.4	75.1
Myeloma	6.5	8.2	5.0	3.0	3.8	2.3	54.5	54.8	54.0
Leukemia:	15.2	19.4	11.8	6.5	8.7	4.9	65.3	65.6	64.9
Lymphocytic:	7.8	10.2	5.7	1.8	2.5	1.2	82.7	82.4	83.0
Acute lymphocytic	1.9	2.2	1.7	0.5	0.6	0.4	70.0	69.1	71.1
Chronic lymphocytic	5.4	7.3	3.9	1.2	1.7	0.8	87.0	86.3	88.1
Other lymphocytic	0.5	0.7	0.2	0.1	0.2	0.1	85.2	88.3	75.4
Myeloid & Monocytic:	6.7	8.3	5.4	3.5	4.6	2.7	42.7	42.2	43.4
Acute myeloid	4.4	5.4	3.7	2.9	3.7	2.2	29.0	27.8	30.4
Chronic myeloid	2.0	2.5	1.5	0.3	0.4	0.2	69.6	68.4	71.4
Acute monocytic	0.2	0.2	0.2	0.0	0.0	0.0	26.2	24.5	28.1
Other myeloid & monocytic	0.1	0.2	0.1	0.3	0.4	0.2	36.2	37.4	34.1
Other leukemia:	0.7	0.9	0.6	1.3	1.7	1.0	49.3	47.7	51.1
Other acute leukemia	0.2	0.3	0.2	0.4	0.5	0.3	26.6	27.3	25.8
Aleukemic, subleukemic & NOS	0.5	0.6	0.4	0.8	1.1	0.6	58.6	56.5	60.8
Kaposi Sarcoma <sup>f</sup>	0.4	0.7	0.1	-	-	-	76.7	75.2	87.9
Mesothelioma <sup>f</sup>	1.0	1.6	0.5	-	-	-	11.0	8.5	18.3
Ill-defined & unspecified	16.4	19.7	13.9	11.7	14.6	9.4	40.6	40.9	40.3

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

<sup>b</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>c</sup> SEER 18 areas. Based on follow-up of patients into 2018. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

<sup>d</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>e</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

<sup>f</sup> Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.